Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Werewolf Therapeutics Inc...

    NASDAQ: HOWL · Real-Time Price · USD
    1.25
    -0.05 (-3.85%)
    At close: Jun 17, 2025, 11:51 AM

    Werewolf Therapeutics Statistics

    Share Statistics

    Werewolf Therapeutics has 44.87M shares outstanding. The number of shares has increased by 3.16% in one year.

    Shares Outstanding

    n/a
    		 44.87M

    Shares Change (YoY)

    n/a
    		 3.16%

    Shares Change (QoQ)

    n/a
    		 0.59%

    Owned by Institutions (%)

    n/a
    		 64.47%

    Shares Floating

    n/a
    		 33.12M

    Failed to Deliver (FTD) Shares

    n/a
    		 1,585

    FTD / Avg. Volume

    n/a
    		 0.37%

    Short Selling Information

    The latest short interest is 2.07M, so 4.62% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 2.07M

    Short % of Shares Out

    n/a
    		 4.62%

    Short % of Float

    n/a
    		 6.54%

    Short Ratio (days to cover)

    n/a
    		 2.49

    Valuation Ratios

    The PE ratio is -0.91 and the forward PE ratio is -0.79. Werewolf Therapeutics's PEG ratio is -0.02.

    PE Ratio

    n/a
    		 -0.91

    Forward PE

    n/a
    		 -0.79

    PS Ratio

    n/a
    		 34.02

    Forward PS

    n/a
    		 0.8

    PB Ratio

    n/a
    		 0.87

    P/FCF Ratio

    n/a
    		 -1.14

    PEG Ratio

    n/a
    		 -0.02
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Werewolf Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 7.45, with a Debt / Equity ratio of 0.51.

    Current Ratio

    n/a
    		 7.45

    Quick Ratio

    n/a
    		 7.45

    Debt / Equity

    n/a
    		 0.51

    Debt / EBITDA

    n/a
    		 -0.58

    Debt / FCF

    n/a
    		 -0.66

    Interest Coverage

    n/a
    		 -15.81

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $40,978.26

    Profits Per Employee

    n/a
    		 $-1,532,934.78

    Employee Count

    n/a
    		 46

    Asset Turnover

    n/a
    		 0.01

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 n/a

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by -58.79% in the last 52 weeks. The beta is 0.66, so Werewolf Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 0.66

    52-Week Price Change

    n/a
    		 -58.79%

    50-Day Moving Average

    n/a
    		 1.01

    200-Day Moving Average

    n/a
    		 1.56

    Relative Strength Index (RSI)

    n/a
    		 56.37

    Average Volume (20 Days)

    n/a
    		 431,333

    Income Statement

    In the last 12 months, Werewolf Therapeutics had revenue of 1.89M and earned -70.52M in profits. Earnings per share was -1.63.

    Revenue

    n/a
    		 1.89M

    Gross Profit

    n/a
    		 71K

    Operating Income

    n/a
    		 -73.59M

    Net Income

    n/a
    		 -70.52M

    EBITDA

    n/a
    		 -64.05M

    EBIT

    n/a
    		 -65.86M

    Earnings Per Share (EPS)

    n/a
    		 -1.63
    Full Income Statement

    Balance Sheet

    The company has 111M in cash and 37.09M in debt, giving a net cash position of 73.91M.

    Cash & Cash Equivalents

    n/a
    		 111M

    Total Debt

    n/a
    		 37.09M

    Net Cash

    n/a
    		 73.91M

    Retained Earnings

    n/a
    		 -414.59M

    Total Assets

    n/a
    		 107.24M

    Working Capital

    n/a
    		 82.79M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -56.19M and capital expenditures -254K, giving a free cash flow of -56.44M.

    Operating Cash Flow

    n/a
    		 -56.19M

    Capital Expenditures

    n/a
    		 -254K

    Free Cash Flow

    n/a
    		 -56.44M

    FCF Per Share

    n/a
    		 -1.3
    Full Cash Flow Statement

    Margins

    Gross margin is 3.77%, with operating and profit margins of -3904.19% and -3740.85%.

    Gross Margin

    n/a
    		 3.77%

    Operating Margin

    n/a
    		 -3904.19%

    Pretax Margin

    n/a
    		 -3740.85%

    Profit Margin

    n/a
    		 -3740.85%

    EBITDA Margin

    n/a
    		 -3397.61%

    EBIT Margin

    n/a
    		 -3904.19%

    FCF Margin

    n/a
    		 -2994.27%

    Dividends & Yields

    HOWL does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for HOWL is $6, which is 365.1% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $6

    Price Target Difference

    n/a
    		 365.1%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 3
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 -5.67

    Piotroski F-Score

    n/a
    		 3

    Add to Watchlist